COMMUNIQUÉS West-GlobeNewswire

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
28/09/2024
- Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month 30 compared with placebo - Additionally, results from a [...]
Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device
27/09/2024
Company to Focus on 510(k) Approval Path, Accelerating Time-to-Market Oak Ridge, TN, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today [...]
CARVYKTI® ▼ (ciltacabtagene autoleucel; cilta-cel) is the first cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
27/09/2024
45 percent reduction in risk of death achieved with cilta-cel versus standard therapies after three-year follow-up in landmark CARTITUDE-4 study 1 Data featured in a late-breaking oral presentation at the 2024 [...]
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
27/09/2024
Landmark CARTITUDE-4 study results show CARVYKTI ® reduced the risk of death by 45 percent after three-year follow-up Late-breaking data featured in an oral presentation at the 21 st International Myeloma Society Annual [...]
DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
27/09/2024
DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update Additional clinical data on patients suffering from Obstructive Sleep Apnea (OSA) demonstrate a clinically [...]
Les Données de l'Étude Pivot DREAM Présentées lors de l'International Surgical Sleep Society 2024 Educational Update
27/09/2024
Les Données de l'Étude Pivot DREAM Présentées lors de l'International Surgical Sleep Society 2024 Educational Update Des données cliniques supplémentaires sur des patients souffrant d'apnée obstructive du sommeil (AOS) [...]
PetMed Express, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
27/09/2024
DELRAY BEACH, Fla., Sept. 27, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. , dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS), today announced that on September 27, 2024, PetMeds granted two equity awards [...]
PacBio Grants Equity Incentive Award to New Employee
27/09/2024
MENLO PARK, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s [...]
Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October
27/09/2024
SAN FRANCISCO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics , a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced that Cory R. [...]
DARZALEX® (daratumumab) subcutaneous (SC) formulation-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned
27/09/2024
Study demonstrates a minimal residual disease (MRD)-negativity rate of 60.9 percent and 43 percent reduction in the risk of progression or death 1 Phase 3 CEPHEUS study results presented in late-breaking oral [...]
Communities Across the Commonwealth Come Together to Celebrate Massachusetts Good Neighbor Day of Action
27/09/2024
-- A broad range of inspiring events including a “Find Your People” fair, intergenerational dinners, a town scavenger hunt, free YMCA admission, and others help people and communities connect-- BOSTON, Sept. 27, 2024 ( [...]
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
27/09/2024
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from SEQUOIA-HCM ( S afety, E fficacy, and Q uantitative U nderstanding of O [...]
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
27/09/2024
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent approvals in the EU and [...]
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
27/09/2024
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype [...]
Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO
27/09/2024
Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO Dupixent est indiqué à environ 300 000 adultes aux États-Unis présentant une BPCO inadéquatement contrôlée et un [...]
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
27/09/2024
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with strategic contract manufacturer and expanding [...]
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
27/09/2024
28-week data show ESK-001 was generally well tolerated and most patients treated with the top dose of 40 mg twice daily achieved PASI 75 Three additional data presentations further support ESK-001’s potential to offer a [...]
Turning Point of Tampa Now In-Network with Blue Cross Blue Shield Insurance
27/09/2024
TAMPA, FL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Turning Point of Tampa, a top-rated addiction treatment facility since 1987, is proud to announce that it is now in-network with Blue Cross Blue Shield, effective September [...]
Burning Rock Announces Changes to Management and Board of Directors
27/09/2024
GUANGZHOU, China, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) (the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in [...]

Pages